Cefepime, E-;Anti-cefepime;E-Cefepime;97164-57-3;149261-27-8;88040-23-7;Cefepime EP Impurity A;Cefepime impurity A [EP];UNII-Z0114Q3738;Cefepime specified impurity A [EP];(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;Z0114Q3738;(6R,7R)-7-(((2E)-(2-Aminothiazol-4-yl)(methoxyimino)acetyl)amino)-3-((1-methylpyrrolidinio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate;Cefepime dihydrochloride monohydrate impurity A [EP];(6R,7R)-7-((E)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((1-methylpyrrolidin-1-ium-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, (6R-(6alpha,7beta(E)))-;Renapime;C19-H24-N6-O5-S2;Cefepime, BMY-2;C6H14N4O2.C19H24N6O5S2.2ClH;Cefepime, Antibiotic for Culture Media Use Only;C6-H14-N4-O2.C19-H24-N6-O5-S2.2Cl-H;SCHEMBL98274;BIDD:GT0809;GTPL10772;DTXSID60164213;HVFLCNVBZFFHBT-ZKDACBOMSA-N;AKOS015895225;CEFEPIME IMPURITY A [EP IMPURITY];F82041;Q2552927;W-204251;CEFEPIME DIHYDROCHLORIDE MONOHYDRATE IMPURITY A [EP IMPURITY];(6R,7R)-7-[[(2E)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(6R,7R)-7-[[(2Z)-2-(2-AMINO-1,3-THIAZOL-4-YL)-2-METHOXYIMINO-ACETYL]AMINO]-3-[(1-METHYL-2,3,4,5-TETRAHYDROPYRROL-1-YL)METHYL]-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLATE;[6R-[6.alpha.,7.beta.(Z)]]-1-[[7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium, hydroxide, inner salt;PYRROLIDINIUM, 1-((7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-1-METHYL-, (6R-(6.ALPHA.,7.BETA.(E)))-